Please login to the form below

Not currently logged in
Email:
Password:

Advagraf

This page shows the latest Advagraf news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf

Committee backs the drug for transplant rejection prophylaxis. European regulatory advisors have recommended approval of Teva Pharmaceutical’s generic version of Astellas’ transplant rejection treatment Advagraf.

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    as well as a once-daily formulation in development as the brand Advagraf (tracrolimus extended release capsules).

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    In transplantation, three years ago we launched Advagraf, a prolonged-release tacrolimus formulation, which offers the consistency of exposure so vital for transplant recipients.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics